

CERTIFICATE

2024

Molekularpathologie-BW GbR
Schloßstraße 56
70176 Stuttgart
Deutschland

has successfully completed the proficiency test

FGFR3 Urothelial Carcinoma (MolPath)

(Trial Period 07.10.2024 - 25.10.2024)

Berlin, 16. Mai 2025



Prof. Dr. med. Claudia Wickenhauser
Quality in Pathology - QuIP GmbH



Thomas Pilz, Managing Director
Quality in Pathology - QuIP GmbH

Lead panel institute of the proficiency test:
Prof. Dr. med. Arndt Hartmann, Dr. med. Veronika Bahlinger, Universitätsklinikum Erlangen

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report, the evaluation criteria can be found in the proficiency test report under point 3.2.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

Approved by: